Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis

By sjmartinez • May 1, 2024

Gu Y, Gebremariam T, Alkhazraji S, Youssef E, El-Gamal S, Matkovits T, Cobb J, Mannino R, Ibrahim AS. Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis. Antimicrob Agents Chemother. 2024 Apr 30:e0154023. doi: 10.1128/aac.01540-23. Epub ahead of print. PMID: 38687015.

Tags: Amphotericin B, antifungal agents, Harbor UCLA, Infectious Diseases, lipid nanocrystal, liposomal amphotericin B, MAT2203, mucor, mucormycosis, murine, oral amphotericin B, Publications, Rhizopus

Aortic valve calcium as a novel risk marker for kidney function deterioration: The MESA study

Abdollahi A, Sani MM, Shabani M, Matuck BS, Blaha MJ, Wu CO, Ambale-Venkatesh B, Budoff MJ, Strom JB, Rotter JI, Post WS, Blumenthal RS, Bluemke[...]

Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study

Karpouzas GA, Ormseth SR, Van Riel P, Myasoedova E, Gonzalez-Gay MA, Corrales A, Rantapaa-Dahlqvist S, Sfikakis P, Dessein P, Hitchon CA, Pascual-Ramos V, Yanez IC,[...]

Bouveret syndrome in 2 parts: endoscopic removal of residual cholelithiasis with closure of cholecystoduodenal fistula after initial surgical management

Cumpian NA, Atla PR, Alao H, Eysselein V, Reicher S. Bouveret syndrome in 2 parts: endoscopic removal of residual cholelithiasis with closure of cholecystoduodenal fistula[...]